EZH2 Inhibition in Ewing Sarcoma Upregulates G(D2) Expression for Targeting with Gene-Modified T Cells

Chimeric antigen receptor (CAR) engineering of T cells allows one to specifically target tumor cells via cell surface antigens. A candidate target in Ewing sarcoma is the ganglioside G(D2), but heterogeneic expression limits its value. Here we report that pharmacological inhibition of Enhancer of Ze...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Mol Ther
Auteurs principaux: Kailayangiri, Sareetha, Altvater, Bianca, Lesch, Stefanie, Balbach, Sebastian, Göttlich, Claudia, Kühnemundt, Johanna, Mikesch, Jan-Henrik, Schelhaas, Sonja, Jamitzky, Silke, Meltzer, Jutta, Farwick, Nicole, Greune, Lea, Fluegge, Maike, Kerl, Kornelius, Lode, Holger N., Siebert, Nikolai, Müller, Ingo, Walles, Heike, Hartmann, Wolfgang, Rossig, Claudia
Format: Artigo
Langue:Inglês
Publié: American Society of Gene & Cell Therapy 2019
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6520468/
https://ncbi.nlm.nih.gov/pubmed/30879952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2019.02.014
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires